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Резюме
Aim. To propose a new type of antiviral treatment for COVID-19, pending the rollout of the developed vaccines and bypassing vaccine resistance of 
the new upcoming mutated virus variants. Aiming for prophylaxis and early therapy, the search focused on small molecules or repurposed, safe, oral 
and inexpensive drugs, also suitable for low-income countries. Methods. A search in peer-reviewed literature for preclinical antiviral mechanisms 
highlighted at last two clinical studies for further detailed clinical analysis: 1) High dose N-acetylcysteine (NAC) was successfully applied in very 
severe COVID-19-pneumonia; 2) The discovery of serum level H2S (hydrogen sulfide) as a prognostic host factor. Results. Combining of these two 
findings resulted in a step-by-step approach with 3 perspectives that describes how H2S works in viral respiratory diseases, how H2S targets at least 
three vulnerabilities in the SARS-CoV-2 virus; finally, how H2S can be generated and with which drugs. More than 3 dozen successful, clinically 
well-documented applications have already been found. Conclusion. By using NAC as the H2S donor, the generated endogenous antiviral H2S 
reactivates the collapsed innate immunity, providing a therapy regimen for COVID-19. Further randomized controlled trials are warranted, 
considering antiviral H2S for inclusion in some master trial protocols.
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Abstract
Целью исследования явилось предложение нового типа противовирусной терапии для больных COVID-19 в ожидании выведения на 
рынок разработанных вакцин в обход устойчивости к вакцинам новых мутаций вируса. Поиск средств для профилактики и ранней 
терапии был сосредоточен на низкомолекулярных препаратах или перепрофилировании безопасных пероральных недорогих препара-
тов, подходящих для применения в т. ч. в странах с низким уровнем доходов. Материалы и методы. При поиске публикаций в рецензи-
руемых журналах рассматривались работы о механизмах защиты от вируса, описанных у животных. Для дальнейшего подробного кли-
нического анализа обнаружены 2 клинических исследования на следующие темы: 1) успешное применение высоких доз N-ацетилци-
стеина (NAC) при очень тяжелой пневмонии COVID-19; 2) подтверждение прогностической роли сывороточного уровня H2S (серово-
дорода) в организме хозяина. Результаты. После объединения результатов указанных исследований поэтапно описаны 3 основных 
аспекта – как H2S работает при вирусных респираторных заболеваниях; как H2S воздействует на уязвимости вируса SARS-CoV-2 по 
крайней мере 3 типов; как и под действием каких лекарств вырабатывается H2S. Обнаружено более 3 десятков успешных примеров 
применения этого механизма с подробными клиническими данными. Заключение. При использовании NAC в качестве донора H2S 
эндогенный противовирусный H2S реактивирует врожденный иммунитет, который противодействует COVID-19. С учетом того, что 
противовирусный H2S может быть включен в некоторые основные протоколы клинических испытаний, необходимы дальнейшие ран-
домизированные контролируемые исследования.
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The coronavirus disease 2019 (COVID-19) caused by the 
novel severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) has developed since December 2019 and 
caused a global pandemic with more than one million 
fatalities globally. Hallmarks of this type of coronavirus 
compared to older types are a high infectivity and more 
severe inflammation.
One year deep into the COVID-19 pandemic we only 
found dexamethasone in the treatment on evidenced 
grounds [1].
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No other antiviral drug candidates have evidence, 
based trial results [2 – 4], neither in the guidelines. The 
current vaccines need also extra time for the logistics and 
obtaining a durable antibody response is also unclear, but 
in the mean, time the danger of a SARS-CoV-2 mutant 
remains [5]. Aside from timely steroids, supportive care, 
anticoagulants and ventilator support, there is no validated 
evidence for antiviral therapy, so we must consider well-de-
signed studies, while waiting for a jab.
Aims. To identify treatments that can be used to treat 
mild and moderate cases of COVID-19 early and prevent 
spikes in hospitalizations that could overwhelm fragile and 
already overburdened health systems in low income coun-
tries. Here we propose a new treatment option in line with 
viral expert professor David Fedson [6].
Materials and Methods
The natural course of corona infection is usually mild, but 
there are known risk factors that can cause deterioration, 
suggesting that a host factor is disturbed by these factors, 
such as hypertension, diabetes, obesity and older age. 
Screening for viral protection in animals, like the in vitro 
and preclinical studies by С.Casola and coworkers (below, 
[10 – 13]), brings hydrogen sulfide (H2S) as a possible an-
tiviral option to our attention.
In this article, we investigate why H2S supplementation 
may be beneficial for the treatment of COVID-19 disease. 
Next, it is important that dissecting the breakdown of 
N-acetylcysteine (NAC) can provide us with insights to 
modulate the level of H2S.
A three-step viewpoint examines whether H2S:
• may be an antiviral host factor;
• may be generated from N-acetylcysteine;
• may act multi-targeted in SARS-CoV-2 infection.
Viewpoint 1. H2S is an antiviral host factor
Recently a clinical study defined serum H2S a prognostic 
factor in COVID-19 [7].
In severe COVID-19 pneumonia cases (n = 74) the 
authors found that for mortality:
• low serum levels of H2S on day 1 had the best trade-off 
for sensitivity and specificity;
• decrease in serum level H2S from day 1 to day 7 greater 
of 36% as the best discriminator;
• mortality after 4 weeks was 32% vs 4.1% for suboptimal 
vs optimal level H2S;
• serum H2S was negatively associated with IL-6, Pro-
calcitonin and CRP;
• the 4 weeks survivors are those who consume less of this 
H2S.
This evidence suggests that the reduction of H2S bio-
availability may be considered as an indicator of enhanced 
pro-inflammatory response and that the administration of 
exogenous H2S may be viewed as a pharmacological strat-
egy to restore H2S plasma levels in order to counteract the 
severe consequences of COVID-19 infection [7].
This also may give rise to a first statement that H2S is 
a Host Factor in COVID-19.
About H2S. H2S is endogenously produced out of sulfur 
amino acids (SAA) like cysteine, and it's level is very strictly 
regulated. After all, H2S was previously known as a poison.
H2S is produced from L-cysteine by cystathionine 
β-synthase (CBS), cystathionine γ-lyase (CSE), and from 
3-mercaptopyruvate (3MP) also mercaptopyruvate sul-
furtransferase (3MST) produces H2S, which is produced 
from cysteine and α-ketoglutarate by cysteine amino-
transferase (CAT). SAA and their derivatives transport 
sulfur through successive oxidation reactions, which then 
also release H2S, which once produced, can travel signif-
icant distances within and between different cell types, 
and can act as an autocrine and paracrine messenger. 
H2S permeates all membranes freely as a gasotransmitter 
(like NO and CO) and unlike classical regulators of signal 
transduction, it acts independently of transmembrane 
receptors [8]. Produced in mammalian tissues, H2S acts 
as biological mediator and signals many important physi-
ological processes in humans. Figure 1 streamlines clearly 
the sulphur redox reactions [9].
Figure 1. H2S release 
(Е.Marutani [9])
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H2S-antiviral evidence in preclinical studies. Anti-viral 
and anti-inflammatory effects
In four preclinical studies the group of С.Casola [10 – 
13] uncovered a critical protective role of H2S in RSV infec-
tion in vitro and in vivo, by modulating innate inflammatory 
responses and viral replication. 
They used enzyme blocking, donor H2S and knock-out 
models and they reduced the viral replication and chemo-
kine secretion by modulation of transcription factors nu-
clear factor (NF)-κB and the interferon regulatory factor 
(IRF)-3. They uncovered two mechanisms that were at 
play. Firstly donor H2S treatment drastically reduced the 
secretion of the cytokines IL-6, TNF-α and G-CSF, as 
well as the chemokines IL-8, RANTES, IP-10, MCP-1 
and MIP-1β from infected cells. Secondly airway epithelial 
cells infected with RSV then display a decreased ability 
to generate endogenous H2S and enhanced degradation 
of H2S, indicating that viral infection leads to changes in 
H2S cellular homeostasis or even to H2S depletion. These 
well-designed preclinical studies provided a solid founda-
tion for the antiviral and anti-inflammatory effects of H2S. 
Therefore, additional studies were expected to elaborate 
on this.
Currently the rationale for using H2S in COVID-19 
is supported in several other studies, such as X.Yang [14], 
М.В.Evgen'ev [15], and V.Citi [16].
The antiviral activity of a series of H2S releasing mole-
cules and reference H2S donors (e.g., GYY4137 and sodium 
hydrosulfide), was first tested and this preliminary screen 
showed that most of the sulfur molecules provided a sig-
nificant antiviral effect.
A disulfide compound (XM-01) was selected for further 
evaluation on both enveloped and non-enveloped viral 
strains, such as RSV, influenza virus (A/WSN/33 strain) 
and rotavirus. As observed in previous GYY4137 studies, 
XM-01 showed antiviral effects on enveloped viruses. Re-
markably, no activity was observed on non-enveloped vi-
ruses such as rotavirus. Since the antiviral activity may be 
due to viral membrane changes, GYY4137 and its analogues 
may be useful against enveloped viruses especially at the 
time of viral entry into the host cell. Recently, a paper hy-
pothesized that H2S may exhibit antiviral activity against 
SARS-CoV-2 by interfering with the ACE2 receptor and 
TMPRSS2 [14].
Viewpoint 2. N-Acetyl cysteine generates H2S
The above preclinical research leads us to suggest that it 
may be useful to generate H2S in mammals. Previous re-
search suggests that NAC is able to do this: R.C.Zanar­
do [17] using intravital microscopy in animals found anti 
inflammatory effects at the leuko-endothelial interface 
induced not only by donor H2S but also by NAC. Inhibi-
tion of the CSE enzyme reversed all these NAC effects. 
This suggested, for the first time to our knowledge, that 
NAC could generate H2S. D.Ezerina [18] confirmed this 
hypothesis about NAC, by dissecting in NAC the anti-
oxidant effect apart from the H2S-generating potential. 
NAC-derived cysteine has been shown to be desulfurat-
ed to generate hydrogen sulfide which is then oxidized 
in mitochondria to sulfane sulfur species. These sulfane 
sulfur species would be the actual substances responsible 
for mediating the antioxidant and cytoprotective effects 
we previously attributed to NAC. A different degradation 
pathway for NAC may be used, via cysteine and 3 MP, to 
generate H2S and sulfane sulfur species such as persul-
fides [18 – 21]; later К.Zuhra [22] confirmed this finding 
and also Р.К.Yadav [23] suggest NAC, serving as a source 
of cysteine, could support MST activity.
It may be appropriate to restore cysteine and H2S levels 
immediately after exhaustion by the SARS-CoV-2 infec-
tion, in order to maintain the antiviral and anti-inflam-
matory effects.
This can be achieved in two different ways:
a) Taurine suppletion:
• In the breakdown of cysteine the CSE enzyme is 
strongly boosted by taurine.
• Taurine increases the expression of the H2S-syn-
thesizing enzymes CBS and CSE, and thereby it 
contributes strongly to increase (doubling) the en-
dogenous H2S level in a human RC trial [24, 25]. 
An animal study supports this principle [20]. This 
option is only apt if there is sufficient substrate (cys-
teine): otherwise consider option b).
b) N-acetylcysteine suppletion:
• Importantly the (extracellular located) NAC in itself 
should not be considered a powerful antioxidant: its 
power is the targeted replenishment of the intracel-
lular glutathione (GSH) stock in deficient cells and 
it is unlikely to be effective in cells already packed 
with GSH. This intracellular GSH stock is available 
for the formation of cysteine. And, if necessary, this 
cysteine can be further desulphurized to produce 
H2S combined with a so-called sulfansulfur (the 
latter is the actual antioxidant).To investigate the 
antiviral therapy against the SARS-CoV-2 virus, 
we opt to use this endogenously produced H2S, by 
administering the prodrug NAC. It is possible now 
to conclude that treatment of cells with the Cys-pro-
drug NAC triggers endogenous H2S production.
Viewpoint 3. H2S acts multi-targeted in SARS-CoV-2 
infection
3a. The Innate Immunity and Amino acids
Suppression-Exhaustion-Suppletion. The components of 
the innate immune system act as first responders for the 
detection and clearance of viral infections. But many viral 
infections evade the host innate immune response, some-
times resulting in a complete Host Shut-Off (reviewed in 
detail [26]).
Then the virus will hijack the host's defenses by total 
capture of the cellular translation machinery for its own 
use.
In addition, the virus bypasses the type I interferon 
(IFN-I) response, which normally promotes an antiviral 
state in both the infected and neighboring cells, limiting 
viral replication and inducing apoptosis to protect the 
organism from virus spread. Indeed, coronaviruses have 
evolved multiple strategies to escape and to counteract 
innate detection and IFN-I production. Such efficient 
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strategies allow the virus to replicate and disseminate in 
infected individuals without encountering the initial host 
defense. While many arms of the innate immune response 
are potently activated by COVID-19, in comparison to 
other respiratory viruses, SARS-CoV-2 infection drives 
a lower antiviral transcriptional response. This is marked 
by low IFN-I and IFN-III levels and elevated chemokine 
expression, suggesting that some aspects of the innate im-
mune response to COVID-19 might actually benefit from 
a more careful amplification [27].
The secretion of both IFN­α and ­β were all reduced 
by donor H2S [13].
Also, significant dysregulation of monocytes and 
macrophages seems to be a feature of severe COVID-19, 
apart from a decrease in T-cell levels, a significantly high-
er neutrophil-to-lymphocyte ratio (NLR) and depleted 
peripheral NK-cell counts. The number of total T-cells, 
CD4+ and CD8+ T-cells were dramatically reduced in 
COVID-19 patients and correlated negatively with sur-
vival [28]. COVID-19 patients show significantly higher 
levels of the exhausted marker PD-1 [29]. T-cell num-
bers in patients were negatively correlated to serum IL-6, 
IL-10, and TNF-α concentration, but H2S can positively 
impact these concentrations. It reduced IL-6 and TNF-
α-induced NF-κB activation. H2S also potentiates T-cell 
activation [30].
On the other hand, SARS-CoV-2 infection also 
caused a rapid depletion of the sulfur-containing amino 
acids (SAA) as a function of oxidant stress or inflamma-
tion-induced proteolysis. Cysteine and taurine levels then 
tended to decrease [31], especially with moderately high 
IL-6. In contrast, oxidized forms of SAA (methionine sulf-
oxide, cystine) increased [31] All together, this will reduce 
the bioavailability of cysteine as a substrate for H2S. Like-
wise NAC treatment safely replenishes whole blood GSH 
and T-cell GSH in HIV-infected persons with a depletion 
of SAA [32, 33]. GSH is a stock for cysteine. A rapid re-
sponse of changes in Cys levels is observed within hours of 
NAC supplementation [34].
3b. NLRP3 Inflammasome
A Potential Drug Target In COVID-19. Although, innate 
immune mechanisms such as optimal activation of the 
NLRP3 inflammasome plays an important role in antivi-
ral host defenses, its aberrant activation and downstream 
mediators often lead to pathological tissue injury during 
infection [35]. Also, infection with SARS-CoV is known to 
induce a storm of pro-inflammatory cytokines, especially 
IL-1β, IL-6, and TNF. These play an important role in 
the progression of tissue inflammation causing acute respi-
ratory distress syndrome ARDS and often leads to death. 
Hydrogen sulfide inhibits NLRP3 inflammasome activation 
and reduces cytokine production [36].
3c. The vascular compartment
ARDS ACE-2 expression endothelioitis coagulation. H2S 
modulates leukocyte-mediated inflammation. In the leu-
ko-endothelial interface it interferes with leukoadhesion 
and leukoinfiltration [17]. In COVID-19 this could have 
some relevance for the complicating ARDS [37] or SIRS 
and other complicating vascular problems like myocardial 
infarction, stroke, thrombo-embolia [38, 39].The ACE2 
receptor is not only necessary for the viral entry in the 
AECs, but the ACE2 receptor is also expressed in the vas-
cular system [40].
SARS-CoV infection reduces ACE2 expression in 
lung cells and that loss of pulmonary ACE2 function is 
associated with acute lung injury. As virus-induced ACE2 
downregulation may be important for disease patholo-
gy, then on the contrary ACE2 upregulation by H2S (as 
shown by Lin [41]) may attenuate the acute lung injury. 
At last, a deficiency of H2S-producing enzymes results in 
hypertension, and administration of H2S donors lowers 
blood pressure and protects against organ damage in the 
experimental setting [42].
3d. Pharmaceutical aspects of N-Acetylcysteine
Disulfide bonds. High Dosing: NAC is used safely for some 
30 years in case of acetaminophen intoxication.
N-Acetylcysteine may be applied as tablet, intravenous-
ly or by nebulization. Its mostly mentioned anti-oxidant 
effect was dissected in 2018 from its H2S generating effect 
in a breakthrough study [18, 19], later confirmed by two 
other studies.
NAC easily penetrates cells where it is deacetylated to 
yield L-cysteine thereby promoting GSH synthesis. There-
fore, NAC works per se in the extracellular environment 
and as a precursor of GSH inside cells. Accordingly, all 
its intracellular effects are mediated by GSH replenish-
ment [43].
NAC has mucolytic properties on sputum by breaking 
disulfide bonds in the mucus, and H2S shows only antiviral 
effects on enveloped viruses, which use a fusion protein for 
the cell entry [16].
The ability to break disulfide bonds may be important 
to this fusion process, as the SARS coronavirus peak S2 
domain is flanked by cysteine residues C822 and C833 and 
this domain is required for membrane fusion activation. 
FP2 has some effect on the membrane sequence.
Two cysteines (C822 and C833) within FP2 are consid-
ered an internal disulfide bond, giving this domain a loop 
structure. It is questionable whether these disulfide bonds 
will resist the local H2S and/or NAC in the membrane 
fusion region [44].
A.L.Lai et al. tested whether such a disulfide bond could 
play a role in the FP2-mediated membrane ordering. They 
found that in the presence of 5 mM dithiothreitol (DTT), 
a reducing agent that removes disulfide bonds, the mem-
brane-ordering effect of FP2 was abrogated [45].
Not only at the cell entry (ACE2 receptor) but also 
in the cytosol it makes sense to consider a same antiviral 
effect. The RNA-dependent RNA polymerase (RdRp), 
also named nsp12 may be a target in SARS-CoV-2. In the 
cytosol this is the central component of the coronaviral 
replication and transcription machinery.
Recently Y.Gao et al. [46] were able to identify an N-ter-
minal β hairpin (D29 to K50) which inserts into the groove 
clamped by the NiRAN domain and the palm subdomain 
in the RdRp domain and forms a set of close contacts to 
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stabilize the overall structure. In the absence of DTT they 
showed C301 to C306 and C487 to C645 to form disul-
fide bonds. But – in the presence of DTT – chelated zinc 
ions were present in the same location as that observed in 
SARS-CoV. So, it is doubtful whether the disulfide bonds 
in the nsp12-nsp7-nsp8 complex of the SARS-CoV-2 virus 
will resist the local effects of H2S and/or NAC.
Note: H2S functions as a gasotransmitter and is not 
bothered by membranes.
3e. Timing of the treatment
Initial virus load and subsequent inflammation. Timing of 
treatment is important when this NAC-Taurine model 
is combined with other antiviral treatments (e.g. Tocili-
zumab; Dexametasone); their sequence is depending on 
the stage of the disease [47]. In one trial, only high-dose 
NAC was given and also started too late without clinical 
benefit [48].
SARS-CoV-2 infection initially has a very high viral 
load at the onset of symptoms, so the early antiviral com-
ponent (e.g. NAC orally or per nebulizer) is important. 
If symptoms are worsening around 7 – 10 days, adding 
dexametasone to NAC should be considered to reverse the 
progressive inflammation.
One thing should be emphasized with the NAC/H2S 
administration:
• only start at an incipient viral infection or a nearby viral 
threat;
• especially with an encapsulated virus. Chronic intake 
of NAC/H2S is not recommended.
Viewpoint 4. Is H2S clinical relevant in COVID-19?
4a. H2S a prognostic factor in severe COVID-19?
A Greek study was published defining serum H2S a prog-
nostic factor in COVID-19 [7].
In COVID-19 pneumonia cases (n = 74) authors found 
that for mortality:
• Low serum levels of H2S on day 1 had the best trade-off 
for sensitivity and specificity;
• A decrease in level H2S from day 1 to day 7 greater of 
36% as the best discriminator;
• The mortality after 4 weeks was 32% vs 4.1% for sub-
optimal vs optimal level H2S;
• Serum H2S was negatively associated with IL-6, Pro-
calcitonin and CRP;
• The 4 weeks survivors are those who consume less of 
this H2S.
This lead to considerations for exogenous H2S supple-
mentation as treatment strategy.
4b. Checking some risk factors in COVID-19, related to low H2S
Risk factors in COVID-19 are known in general. Never-
theless, a number of risk factors for a serious course have 
been found that may suggest a relationship with H2S levels:
• Gender risk: more men then women affected: Firstly 
it may relate to the ACE2 gene, only located on the 
X chromosomes. In addition: estrogen boosts expres-
sion of CSE in the vasculature, so boosting generation 
of H2S [49];
• Hypertension: a deficiency of H2S-producing en-
zymes [42];
• Diabetes: the lower H2S blood values [50];
• Obesity: blood levels of H2S were twice as low vs nor-
mal [51];
• Advanced age: the efficiency of glutathione synthesis and 
glutathione tissue levels decline with age. This age-re-
lated deficit in GSH can be corrected with supplemental 
NAC [52]. From that GSH stock, cysteine generates 
H2S;
• Young patients, ages 2 – 15 yrs: Multisystem inflamma-
tory syndrome in children (MIS-C) is a serious con-
dition that appears to be linked to coronavirus disease 
2019 (COVID­19) with inflammation in multiple organ 
systems and features of Kawasaki disease following to 
SARS-CoV-2 infection; in the acute phase, plasma H2S 
is low [53];
Figure 2. Receptor – 
Fusion peptide – target  
for NAC and H2S [45]
Рис. 2. Рецептор –  
пептид слияния,  
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• Beneficial course in infants and toddlers: taurine in breast 
milk or added to bottled milk, increases the H2S syn-
thesis [21].
4c. Successful Case reports (n = 37):
• H.Ibrahim [54] described 10 consecutive patients with 
severe COVID (10 on ventilator and 9 on ECMO) with 
good clinical response on high dose NAC, with corre-
sponding decrease in CRP and ferritine. No mortality 
here, quite unexpected (expected 37.4% [55]). Steroids 
were also administered.
• V.V.Gaynitdinova [56]; In a RC trial intravenous NAC 
1,200 – 1,500 mg/day (n = 24) was compared to stan-
dard (hydroxychloroquine, azithromycine, enoxa-
parine and dexametasone; and tocilizumab when CRP 
≥ 60 mg/l). NAC safely and effectively attenuated ox-
ygenation, CT patterns and inflammation parameters 
in stage II hospital COVID pneumonia, effects were 
ascribed to glutathione suppletion.
• R.I.Horowitz [57] described in 2 COVID patients im-
mediate improvement after suppletion with glutathione 
(GSH) and NAC. Worth to mention: NAC is a direct 
precursor of GSH. Glutathione inhibits viral replication 
in mice [58].
• С.Puyo [59] succesfully treated one critical ill COVID 
patient with high dose NAC intravenously at 75 mg/kg 
over 4 hours, then 35 mg/kg over 16 hours, followed 
by 17 mg/kg over 24 hours on Day 2. Also HCQ was 
given on day 1 and day 2. Detailed clinical parameters 
showed fast improvement, although a complicating
• Тrombo embolic activation was seen.
4d. Trials in progress (as off augustus-2020):
Additional research on NAC in COVID-19 is started in 
3 clinical trials (USA and China):
• NCT04419025; Boston Cambridge Health Alliance;
• NCT04279197; Shanghai ShuGuang Hospital;
• NCT04374461; Memorial Sloan Kettering Cancer Cen-
ter NY.
Caution! If only NAC is started and too late (later then 
7 – 10 days after the onset of symptoms) and no course of 
steroids is added around that time, then the clinical result 
will be negative (J.C.G. de Alencar [47]). H.K.Siddiqi [46] 
proposed a logical sequence in medication.
4e. NAC used in other (NON-Corona) viral states
Influenza and HIV­1:
• In influenza NAC was effective with a lower incidence 
and lower burden of disease in a predominant elderly 
cohort [60]. Oral N-acetylcysteine did not prevent viral 
infection, but with equal rate of seroconversion strong-
ly reduced the incidence of clinically apparent H1N1 
disease (NAC 25% vs 75% placebo).
• Severe H1N1 Influenza pneumosepsis was treated 
with high dose NAC (100 mg/kg) continuous 3 days. 
Figure 3. The Timing of Treatment in COVID-19 [47]
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It showed (twice) a fast improvement in weaning, ox-
ygenation and CRP [61]. However different influenza 
strains show different effects of NAC [62].
• In HIV-1 patients: Lower concentration in blood of 
cystine, tryptophan and methionine were suppleted 
with oral NAC [63]. The concentrations of cysteine and 
glutathione increased in mononuclear cells of patients 
with HIV infection [64].
Sadly no H2S was measured in these studies.
Discussion
This review reveals a role for endogenous hydrogen sulfide 
(H2S) as a fundamental defense mechanism against viral 
infections by three steps:
1) H2S is acting as an antiviral host factor;
2) Endogenous H2S can be generated by N-acetylcys-
teine (NAC) and taurine;
3) H2S acts multi-targeted in SARS-CoV-2 infection.
• Based on the studies reviewed above (in vitro, in vivo, 
preclinical and clinical), H2S emerged as a host factor 
for viral infections, while in addition the serum H2S 
level was attributed a role as a prognostic marker of 
COVID-19 pneumonia.
In corona the natural clinical course is usually in 80% 
mild; in 15% a desaturation requiring hospitalization occurs 
and in 5% ICU care is needed. This primary natural healing 
process suggests that an antiviral host factor is active here, 
but that some risk factors are disturbing that natural course: 
gender risk, diabetes, obesity, advanced age, in contrast 
to beneficial course in infants and toddlers. These were 
already checked in paragraph 4b.
• The possibility that NAC could act as an H2S donor 
was initially in 2016 demonstrated by R.C.Zanar­
do [17] and in 2018 by D.Ezerina [18]; then endorsed 
by others in 2019 and 2020. This finding has since 
been somewhat overlooked or ignored, with more 
emphasis on the often cited “antioxidant” activity 
(which is actually only related to the sulfane-sulfur 
component) and less emphasis on the associated H2S 
release by NAC.
• COVID-19 can be viewed from two treatment sides: 
X.Yang [14] looked at it from a “H2S point of view”, 
while F.Poe, J.Corn [65] and S. de Flora [43] from 
a “NAC as an anti-oxidant” position. In fact, we may 
conclude that they are all looking at the same pro-
cess and we are not surprised that the results are the 
same or match flawlessly. Both pathways (antioxidant 
and H2S) signal via oxidation reactions with protein 
cysteine sulfur and both produce identical effector 
responses [66].
• Multiple targets can be used by H2S against the coro-
navirus, such as cell entry, the virus replication and the 
escalation of inflammation to a cytokine storm, which 
were also targets explored in the recent drug trials, as 
mentioned in the introduction.
The attack of the virus suddenly collapses both the cel-
lular innate immunity as well the (supply of) sulfur amino 
acids. The latter ensures that H2S decreases quickly.
On the other hand, to correct this acutely, the genera-
tion of endogenous H2S also appears to be a very dynamic, 
fast-acting process and this suggests that, from a safety 
standpoint, H2S will immediately degrade once it has ful-
filled its function.
But even in severe cases of COVID-19, a fast and high 
dose of NAC appears to have sufficient effect for supple-
mentation, according to the clinical success in the patient 
cases [54] This safety is also evidenced by the relatively low 
serum and tissue concentrations measured in vivo versus the 
high and fast concentrations by the artificial H2S donors in 
the previous in vitro studies. Endogenous H2S generation is 
apparently safe, but further intensive dose finding studies 
are warranted, especially when administered in the high 
dose range.
The rationale for using H2S in COVID-19 is supported 
in 4 other studies, like X.Yang [14]; V.Citi [16]; М.В.Ev­
gen'ev [15]; М.Datillo [53], but in those studies the use of 
H2S has not been linked to NAC as a H2S donor.
On the other side F.Poe, J.Corn [65] and S. de Flora [43] 
investigate a rationale for using NAC in COVID-19, but 
then again without regarding the H2S generation power 
of NAC.
Also, the timing of combination in treatment is very 
important and is determined by the ratio of the viral load 
to inflammation. By starting antiviral therapy in a timely 
manner and then containing the inflammatory process at 
an early stage, it is possible to prevent the disease from 
developing and causing severe damage during the inflam-
mation phase [46]. NAC only, and started too late was 
without clinical benefit [48].
Preferentially the viral killing therapy (NAC, orally 
or by nebulizer) is introduced in an early phase. Steroids 
[e.g. dexametason] in the second phase, will follow the 
evidence of the Recovery trial [1].
The large safety margin of NAC and the various options 
in its administration make it possible to scale up with the 
time course and severity of the SARS-CoV-2 infection, 
starting with prevention in case of (suspected) virus con-
tact, via home medication [home confinement for isolation 
or for quarantaine] to hospital or ICU application.
A proposal for such an incremental therapy is on 
a Poster “Adapted Incremental Treatment Plan in 
COVID-19” [67].
The repurposed drug NAC used here, is over-the-
counter, very safe, without side effects, and cheap, making 
it very feasible for conducting randomized controlled clini-
cal trials [6] especially in low income countries. DNDi [68] 
works closely with 26 prominent African and global re-
search and development (R&D) organizations to coordi-
nate the rapid acceleration of development for promising 
medical countermeasures at 19 sites in 13 countries by the 
ANTICOV consortium. It would be worthwhile to con-
sider NAC for inclusion in one of the ANTICOV master 
protocols.
NAC as a endogenous H2S generator reactivates the 
collapsed innate immunity in COVID-19 but off course it 
is also clear that not one drug alone will give a sufficient 
effect.
An intelligent combination of different drugs may prove 
necessary, but even if it is not possible to fully suppress the 
virus, also a mild course with less hospitalizations or ICU 
admissions, will suffice.
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Conclusion
The described process of endogenous H2S generation 
provides us with a multi-targeted antiviral Host Factor in 
COVID-19 infection by reactivating the collapsed innate 
immunity. The use of this endogenously generated H2S as 
a pharmacological antiviral agent is already supported by 
the successful results in now three dozen case studies in 
very severe COVID pneumonia.
We may assume that the milder phases of COVID-19 
may also be treatable with this antiviral host factor, perhaps 
even preventively, avoiding unwanted socio-economic mea-
sures and healthcare overload.
References / Литература
1. RECOVERY Collaborative Group, Horby P., Lim W.S. et al. Dexa-
methasone in hospitalized patients with Covid-19. N. Engl. J. Med. 
2021; 384 (8): 693–704. DOI: 10.1056/NEJMoa2021436.
2. Mehra M.R., Desai S.S., Kuy S. et al. Retraction: cardiovascular 
disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. 
DOI: 10.1056/NEJMoa2007621. N. Engl. J. Med. 2020; 382 (26): 
2582. DOI: 10.1056/NEJMc2021225.
3. Moynihan R., Macdonald H., Bero L., Godlee F. Commercial influence 
and COVID-19. BMJ. 2020; 369: m2456. DOI: 10.1136/bmj.m2456.
4. Boulware D.R., Pullen M.F., Bangdiwala A.S. et al. A random-
ized trial of hydroxychloroquine as postexposure prophylaxis for 
COVID-19. N. Engl. J. Med. 2020; 383 (6): 517–525. DOI: 10.1056/
NEJMoa2016638.
5. Korber B., Fischer W.M., Gnanakaran S. et al. Tracking changes in 
SARS-CoV-2 spike: Evidence that D614G increases infectivity of the 
COVID-19 virus. Cell. 2020; 182 (4): 812–827e19. DOI: 10.1016/j.
cell.2020.06.043.
6. Fedson D.S. Treating the host response to emerging virus diseases: 
Lessons learned from sepsis, pneumonia, influenza and Ebola. Ann. 
Transl. Med. 2016; 4 (21): 421. DOI: 10.21037/atm.2016.11.03.
7. Renieris G., Katrini K., Damoulari C. et al. Serum hydrogen 
sulfide and outcome association in pneumonia by the SARS-
CoV-2 coronavirus. Shock. 2020; 54 (5): 633–637. DOI: 10.1097/
SHK.0000000000001562.
8. Wang R. Two's company, three's a crowd: can H2S be the third en-
dogenous gaseous transmitter? FASEB J. 2002: 16 (13): 1792–1798. 
DOI: 10.1096/fj.02-0211hyp.
9. Marutani E., Ichinose F. Emerging pharmacological tools to control 
hydrogen sulfide signaling in critical illness. Intensive Care Med. Exp. 
2020; 8 (1): 5. DOI: https://doi.org/10.1186/s40635-020-0296-4.
10. Li H., Ma Y., Escaffre O. et al. Role of hydrogen sulfide in paramyxo-
virus infections. J. Virol. 2015: 89 (10): 5557–5568. DOI: 10.1128/
jvi.00264-15.
11. Bazhanov N., Escaffre O., Freiberg A. N. et al. Broad-range antiviral 
activity of hydrogen sulfide against highly pathogenic RNA viruses. 
Sci. Rep. 2017: 7: 41029. DOI: 10.1038/srep41029.
12. Bazhanov N., Ansar M., Ivanciuc T. et al. Hydrogen sulfide: A novel 
player in airway development, pathophysiology of respiratory diseas-
es, and antiviral defenses. Am. J. Respir. Cell Mol. Biol. 2017; 57 (4): 
403–410. DOI: 10.1165/rcmb.2017-0114TR.
13. Ivanciuc T., Sbrana E., Ansar M. et al. Hydrogen sulfide is an antiviral 
and antiinflammatory endogenous gasotransmitter in the airways. 
Role in respiratory syncytial virus infection. Am. J. Respir. Cell Mol. 
Biol. 2016; 55 (5): 684–696. DOI: 10.1165/rcmb.2015-0385OC.
14. Yang G. H2S as a potential defense against COVID-19? Am. 
J. Physiol. Cell Physiol. 2020; 319 (2): C244–249. DOI: 10.1152/
ajpcell.00187.2020.
15. Evgen'ev M.B., Frenkel A. Possible application of H2S-producing 
compounds in therapy of coronavirus (COVID-19) infection and 
pneumonia. Cell Stress Chaperones. 2020; 25 (5): 713–715. DOI: 
10.1007/s12192-020-01120-1.
16. Citi V., Martelli A., Brancaleone V. et al. Anti-inflammatory and an-
tiviral roles of hydrogen sulfide: Rationale for considering H2S donors 
in COVID-19 therapy. Br. J. Pharmacol. 2020; 177 (21): 4931–4941. 
DOI: 10.1111/bph.15230.
17. Zanardo R. C., Brancaleone V., Distrutti E. et al. Hydrogen sulfide 
is an endogenous modulator of leukocyte-mediated inflammation. 
FASEB J. 2006; 20 (12): 2118–2120. DOI: 10.1096/fj.06-6270fje.
18. Ezerina D., Takano Y., Hanaoka K. et al. N-acetyl cysteine functions 
as a fast-acting antioxidant by triggering intracellular H2S and sulfane 
sulfur production. Cell Chem. Biol. 2018; 25 (4): 447–459e4. DOI: 
10.1016/j.chembiol.2018.01.011.
19. Cerda M. M., Pluth M.D. S marks the spot: linking the antioxi-
dant activity of N-acetyl cysteine to H2S and sulfane sulfur species. 
Cell Chem. Biol. 2018: 25 (4): 353–355. DOI: 10.1016/j.chembi-
ol.2018.04.001.
20. Zhao H., Qu J., Li Q. et al. Taurine supplementation reduces neu-
roinflammation and protects against white matter injury after intra-
cerebral hemorrhage in rats. Amino Acids. 2018; 50 (3-4): 439–451. 
DOI: 10.1007/s00726-0172529-8.
21. Di Nicolantonio J.J., O,Keefe J.H., McCarty M.F. Boosting endog-
enous production of vasoprotective hydrogen sulfide via supplemen-
tation with taurine and N-acetylcysteine: a novel way to promote car-
diovascular health. Open Heart. 2017; 4 (1): e000600. DOI: 10.1136/
openhrt-2017-000600.
22. Zuhra K., Tomé C.S., Masi L. et al. N-acetylcysteine serves as sub-
strate of 3-Mercaptopyruvate sulfurtransferase and stimulates sul-
fide metabolism in colon cancer cells. Cells. 2019; 8 (8): 828. DOI: 
10.3390/cells8080828.
23. Yadav P.K., Vitvitsky V., Carballal S. et al. Thioredoxin regulates 
human mercaptopyruvate sulfurtransferase at physiologically-rele-
vant concentrations. J. Biol. Chem. 2020; 295 (19): 6299–6311. DOI: 
10.1074/jbc.RA120.012616.
24. Sun Q., Wang B., Li Y. et al. Taurine supplementation lowers 
blood pressure and improves vascular function in prehypertension: 
randomized, double-blind, placebo-controlled study. Hyperten­
sion. 2016; 67 (3): 541–549. DOI: 10.1161/HYPERTENSIONA-
HA.115.06624.
25. Zaorska E., Tomasova L., Koszelewski D. et al. Hydrogen sulfide in 
pharmacotherapy, beyond the hydrogen sulfide-donors. Biomolecules. 
2020; 10 (2): 323. DOI: 10.3390/biom10020323.
26. Kikkert M. Innate immune evasion by human respiratory RNA vi-
ruses. J. Innate Immun. 2020; 12 (1): 4–20. DOI: 10.1159/000503030.
27. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C. et al. Imbalanced 
host response to SARS-CoV-2 drives development of COVID-19. 
Cell. 2020; 181 (5): 1036–1045.e9. DOI: 10.1016/j.cell.2020.04.026
28. Vardhana S.A., Wolchok J.D. The many faces of the anti-COVID im-
mune response. J. Exp. Med. 2020; 217 (6): e20200678. DOI: 10.1084/
jem.20200678.
29. Yang L., Liu S., Liu J. et al. COVID-19: immunopathogenesis and 
immunotherapeutics. Signal Transduct. Target. Ther. 2020; 5 (1): 128. 
DOI: 10.1038/s41392-020-00243-2.
30. Miller T.W., Wang E.A., Gould S. et al. Hydrogen sulfide is an en-
dogenous potentiator of T cell activation. J. Biol. Chem. 2012; 287 (6): 
4211–4221. DOI: 10.1074/jbc.M111.307819.
31. Thomas T., Stefanoni D., Reisz J.A. et al. COVID-19 infection alters 
kynurenine and fatty acid metabolism, correlating with IL-6 levels 
and renal status. JCI Insight. 2020; 5 (14): e140327. DOI: 10.1172/jci.
insight.140327.
32. De Rosa S.C., Zaretsky M.D., Dubs J.G. et al. N-acetylcysteine 
replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 2000; 
30 (10): 915–929. DOI: 10.1046/j.1365-2362.2000.00736.x.
33. Dröge W. Cysteine and glutathione deficiency in AIDS patients: 
a rationale for the treatment with N-acetylcysteine. Pharmacology. 
1993; 46 (2): 61–65. DOI: 10.1159/000139029.
34. Stipanuk M.H., Ueki I., Dominy J.E. et al. Cysteine dioxygenase: 
a robust system for regulation of cellular cysteine levels. Amino Acids. 
2009; 37 (1): 55–63. DOI: 10.1007/s00726-008-0202-y.
35. da Costa L.S., Outlioua A., Anginot A. et al. RNA viruses promote 
activation of the NLRP3 inflammasome through cytopathogenic 
effect-induced potassium efflux. Cell Death Dis. 2019; 10 (5): 346. 
DOI: 10.1038/s41419-019-1579-0.
36. Castelblanco M., Lugrin J., Ehirchiou D. et al. Hydrogen sulfide 
inhibits NLRP3 inflammasome activation and reduces cytokine pro-
duction both in vitro and in a mouse model of inflammation. J. Biol. 
Chem. 2018; 293 (7): 2546–2557. DOI: 10.1074/jbc.m117.806869.
37. Gattinoni L., Chiumello D., Rossi S. COVID-19 pneumonia: ARDS 
or not? Crit. Care. 2020; 24 (1): 154. DOI: 10.1186/s13054-020-
02880-z.
644 Пульмонология ● Pul’monologiya. 2021; 31 (5): 636–644. DOI: 10.18093/0869-0189-2021-31-5-636-644
Ed J. van Hezik. Importance of antiviral H2S in treatment protocols for COVID-19
38. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence 
of thrombotic complications in critically ill ICU patients with 
COVID-19. Thromb. Res. 2020; 191: 145–147. DOI: 10.1016/j.throm-
res.2020.04.013.
39. Wang B., Yee Aw. T., Stokes K.Y. N-acetylcysteine attenuates systemic 
platelet activation and cerebral vessel thrombosis in diabetes. Redox 
Biology. 2018, 14, 218–228. DOI: 10.1016/j.redox.2017.09.005.
40. Hamming I., Timens W., Bulthuis M. et al. Tissue distribution of 
ACE2 protein, the functional receptor for SARS coronavirus. A first 
step in understanding SARS pathogenesis. J. Pathol. 2004; 203 (2): 
631–637. DOI: 10.1002/path.1570.
41. Lin Y., Zeng H., Gao L. et al. Hydrogen sulfide attenuates atheroscle-
rosis in a partially ligated carotid artery mouse model via regulating 
angiotensin converting enzyme 2 expression. Front. Physiol. 2017; 
8: 782. DOI: 10.3389/fphys.2017.00782.
42. van Goor H., van den Born J.C., Hillebrands J.L., Joles, J.A. Hy-
drogen sulfide in hypertension. Curr. Opin. Nephrol. Hypertens. 2016. 
25 (2): 107–113. DOI: 10.1097/MNH.0000000000000206.
43. De Flora S., Balansky R., La Maestra S. Rationale for the use 
of N-acetylcysteine in both prevention and adjuvant therapy of 
COVID-19. FASEB J. 2020; 34 (10): 13185–13193. DOI: 10.1096/
fj.202001807.
44. Madu I.G., Belouzard S., Whittaker G.R. SARS-coronavirus spike 
S2 domain flanked by cysteine residues C822 and C833 is important 
for activation of membrane fusion. Virology. 2009; 393 (2): 265–271. 
DOI: 10.1016/j.virol.2009.07.038.
45. Lai A.L., Millet J.K., Daniel S. et al. The SARS-CoV fusion peptide 
forms an extended bipartite fusion platform that perturbs membrane 
order in a calcium-dependent manner. J. Mol. Biol. 2017; 429 (24): 
3875–3892. DOI: 10.1016/j.jmb.2017.10.017.
46. Gao Y., Yan L., Huang Y. et al. Structure of the RNA-dependent 
RNA polymerase from COVID-19 virus. Science. 2020; 368 (6492): 
779–782. DOI: 10.1126/science.abb7498.
47. Siddiqi H.K., Mehra M.R. COVID-19 Illness in native and im-
munosuppressed states: A clinical-therapeutic staging proposal. 
J. Heart Lung Transplantat. 2020; 39 (5): 405–407. DOI: 10.1016/j.
healun.2020.03.012.
48. de Alencar J.C.G., Moreira C.L., Müller A.D. et al. Double-blind, 
randomized, placebo-controlled trial with N-acetylcysteine for treat-
ment of severe acute respiratory syndrome caused by coronavirus 
disease 2019 (COVID-19). Clin. Infect. Dis. 2020; 72 (11): e736–741. 
DOI: 10.1093/cid/ciaa1443.
49. Li H., Mani S., Wu L. et al. The interaction of estrogen and CSE/
H2S pathway in the development of atherosclerosis. Am. J. Physi­
ol. Heart Circ. Physiol. 2017; 312 (3): H406–414. DOI: 10.1152/
ajpheart.00245.2016.
50. Jain M., Chandel N.S. Rethinking antioxidants in the intensive care 
unit. Am. J. Respir. Crit. Care Med. 2013; 188 (11): 1283–1285. DOI: 
10.1164/rccm.201307-1380CP.
51. Whiteman M., Gooding K.M., Whatmore J.L. et al. Adiposity is 
a major determinant of plasma levels of the novel vasodilator hydro-
gen sulphide. Diabetologia. 2010; 53 (8): 1722–1726. DOI: 10.1007/
s00125-010-1761-5.
52. Sekhar R.V., Patel S.G., Guthikonda A.P. et al. Deficient synthesis 
of glutathione underlies oxidative stress in aging and can be corrected 
by dietary cysteine and glycine supplementation. Am. J. Clin. Nutr. 
2011; 94 (3): 847–853. DOI: 10.3945/ajcn.110.003483.
53. Dattilo M. The role of host defences in Covid 19 and treatments thereof. 
Mol. Med. 2020; 26 (1): 90. DOI: 10.1186/s10020-020-00216-9.
54. Ibrahim H., Perl A., Smith D. et al. Therapeutic blockade of in-
flammation in severe COVID-19 infection with intravenous N-ace-
tylcysteine. Clin. Immunol. 2020; 219: 108544. DOI: 10.1016/j.
clim.2020.108544.
55. Barbaro R.P., MacLaren G., Boonstra P.S. et al. Extracorporeal mem-
brane oxygenation support in COVID-19: an international cohort study 
of the extracorporeal life support organization registry. Lancet. 2020; 
396 (10257): 1071–1078. DOI: 10.1016/S0140-6736(20)32008-0.
56. Gaynitdinova V.V., Avdeev S.N., Merzhoeva Z.M. et al. [N-ace-
tylcysteine as a part of complex treatment of moderate COVID-as-
sociated pneumonia]. Pulmonologiya. 2021; 31 (1): 21–29. DOI: 
10.18093/0869-0189-2021-31-1-21-29 (in Russian). / Гайнитдино-
ва В.В., Авдеев С.Н., Мержоева З.М. и др. Опыт применения 
N-ацетилцистеина в комплексном лечении среднетяжелой 
COVID-ассоциированной пневмонии. Пульмонология. 2021; 
31 (1): 21–29. DOI: 10.18093/0869-0189-2021-31-1-21-29.
57. Horowitz R.I., Freeman P.R., Bruzzese J.J. Efficacy of glutathione 
therapy in relieving dyspnea associated with COVID-19 pneumonia: 
A report of 2 cases. Respir. Med. Case Rep. 2020; 30: 101063. DOI: 
101063.doi:10.1016/j.rmcr.2020.101063.
58. Amatore D., Celestino I., Brundu S. et al. Glutathione increase by 
the n-butanoyl glutathione derivative (GSH-C4) inhibits viral repli-
cation and induces a predominant Th1 immune profile in old mice 
infected with influenza virus. FASEB Bioadv. 2019; 1 (5): 296–305. 
DOI: 10.1096/fba.2018-00066.
59. Puyo C., Kreig D., Saddi V. et al. Case Report: Use of hydroxychlo-
roquine and N-acetylcysteine for treatment of a COVID-19 posi-
tive patient. F1000Research. 2020; 9: 491. DOI: 10.12688/f1000re-
search.23995.1.
60. De Flora S., Grassi C., Carati L. Attenuation of influenza-like 
symptomatology and improvement of cell-mediated immunity with 
long-term N-acetylcysteine treatment. Eur. Respir. J. 1997; 10 (7): 
1535–1541. DOI: 10.1183/09031936.97.10071535.
61. Lai K.Y., Ng W.Y., Osburga Chan P.K. High-dose N-acetylcysteine 
therapy for novel H1N1 influenza pneumonia. Ann. Intern. Med. 2010; 
152 (10): 687–688. DOI: 10.7326/0003-4819-152-10-201005180-
00017.
62. Garigliany M.M., Desmecht D.J. N-acetylcysteine lacks universal in-
hibitory activity against influenza A viruses. J. Negat. Results Biomed. 
2011; 10: 5. DOI: 10.1186/1477-5751-10-5.
63. Hortin G.L., Landt M., Powderly W.G. Changes in plasma amino 
acid concentrations in response to HIV-1 infection. Clin. Chem. 1994; 
40 (5): 785–789. DOI: 10.1093/clinchem/40.5.785.
64. de Quay B., Malinverni R., Lauterburg B.H. Glutathione depletion 
in HIV-infected patients: role of cysteine deficiency and effect of oral 
N-acetylcysteine. AIDS. 1992; 6 (8): 815–820. Available at: https://
journals.lww.com/aidsonline/Abstract/1992/08000/Glutathione_de­
pletion_in_HIV_infected_patients_.8.aspx
65. Poe F.L., Corn J. N-Acetylcysteine: A potential therapeutic agent for 
SARS-CoV-2. Med. Hypotheses. 2020; 143: 109862. DOI: 10.1016/j.
mehy.2020.109862.
66. Olson K.R. Reactive oxygen species or reactive sulfur species: why we 
should consider the latter. J. Exp. Biol. 2020; 223 (Pt 4): jeb196352. 
DOI: 10.1242/jeb.196352.
67. van Hezik E.J. Adapted incremental treatment plan in COVID-19 - 
version nov 2020: poster. DOI: 10.13140/RG.2.2.19955.04643.
68. Innsamlingskontrollen. Drugs for Neglected Diseases initiative 
(DNDi). Available at: https://www.innsamlingskontrollen.no/organ­
isasjoner/drugs­for­neglegted­diseases­initiative­dndi/
Received: April 01, 2021
Accepted for publication: September 14, 2021
Поступила: 01.04.21
Принята к печати: 14.09.21
Author Information / Информация об авторе
Ed J. van Hezik, M.D. Senior Consultant Chest Physician, Waterfront at Sea – 
a non­profit working group, Netherlands; tel.: +3 (161) 829-92-09; e-mail: 
WaterfrontClinicalConsultants@gmx.com (ORCID: https://orcid.org/0000­
0003­2124­8745)
van Hezik E.J.  – доктор медицины, старший внештатный пульмонолог, 
Некоммерческая рабочая группа “Waterfront at Sea”, Нидерланды; 
тел.: +3 (161) 829-92-09; e-mail: WaterfrontClinicalConsultants@gmx.com 
(ORCID: https://orcid.org/0000­0003­2124­8745)
